Evaluation of Systemic Bioavailability and Effects on 24-Hour Plasma Cortisol Profile of 6 mg Delivered Once Daily Versus 3 mg Delivered Twice Daily in Healthy Adult Male Volunteers

Explorative Study of the Safety/Tolerability of Beclomethasone Dipropionate Suppositories: Evaluation of Systemic Bioavailability and Effects on 24-Hour Plasma Cortisol Profile of 6 mg Delivered Once Daily Versus 3 mg Delivered Twice Daily in Healthy Adult Male Volunteers

Single-centre, randomized, double-blind, two-period, two-sequence, cross-over 7-day study.

This study is the first safety/tolerability evaluation of a product -suppository formulation containing 6 mg BDP (once daily dosing), a second-generation oral or rectal corticosteroids with high topical anti-inflammatory efficacy in the gut and minimal systemic bioavailability (BA).

BDP is marketed in different pharmaceutical formulations, including 3 mg suppositories, and approved for ulcerative proctosigmoiditis in the first attack or exacerbation phase at the dosage of 3 mg twice a day. For these reasons, a 6 mg suppository (Test - "T" product) is a scale-up of the 3 mg formulation (Reference - "R" product).

For locally-applied-locally acting drug products that result in quantifiable systemic availability due to absorption from the administration site, relative systemic BA is informative for safety, but also with respect to efficacy. Therefore, safety/tolerability of T is evaluated through a comparison to R.

Study Overview

• Status: Completed
• Conditions: Healthy Adult Male Volunteers
• Intervention / Treatment: Drug: Beclomethasone dipropionate

Detailed Description

Primary objective is the evaluation of systemic safety of T, based on valid surrogate outcomes - systemic BA (relative BA) at the start of treatment (first 24 hours) and after 7 days of continuous treatment; effects on the hypothalamo-pituitary-adrenal axis (HPA) assessed based on 24-hour cortisol profile after 7 days of continuous treatment. This includes identification of subjects with cortisol levels <10 μg/dL at the last sampling point in the 24-hour cortisol profile (08:00 a.m. on Day 8). In such cases, identified subjects will undergo ACTH stimulation test in the morning of Day 9.

Secondary objective is the evaluation of safety/tolerability based on clinical and laboratory adverse events.

• Study Type: Interventional
• Enrollment (Actual): 28
• Phase: Phase 1

Contacts and Locations

Study Locations

• Italy
  • Verona, Italy, 37134
    • Centro Ricerche Cliniche AOU Integrata di Verona - Policlinico Universitario G.B. Rossi

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Healthy male, aged between 18 and 55 years. Healthy subjects are defined as individuals who are free from clinically significant illness or disease as determined by their medical history, physical examination, laboratory and other (e.g. ECG) tests.
• BMI 19.0 - 29.0 kg/m2;
• Signed and dated written informed consent of the subject to participate in the clinical study;
• The subject is willing to refrain from the use of illicit drugs and alcohol and to adhere to other protocol-stated restrictions while participating in the study;
• The subject is able to understand and comply with the protocol requirements and instructions and is likely to complete the study as planned;
• Non-smoker for at least 3 months.

Exclusion Criteria:

• Subject with a significant abnormality in the past and/or at the Screening that influences the present general health condition and requires pharmacological treatment during the study;
• History of serious allergic diseases, including allergy to medicinal products, which in opinion of the investigator, contraindicates participation to the trial;
• History of diseases of the alimentary tract, liver or kidneys that may influence absorption, distribution and elimination;
• History of average alcohol consumption;
• Hypersensitivity to BDP or study products inactive ingredients;
• Use of any pharmacological treatments (including high dose vitamins, lozenges, herbal and dietary supplements), with the exception of paracetamol ≤ 1 g/daily, within 15 days before the admission to the study Site in the Period 1;
• Use of steroids, anabolic or hormonal therapy within 3 months before the admission to the study Site in the Period 1;
• Laboratory indication of adrenocortical dysfunction;
• Blood loss exceeding 200 ml over the last 4 weeks before the day of Screening;
• Positive results to Sars Cov-2 nasopharyngeal swab;
• Positive results of HBsAg, anti-HCV, anti-HIV tests;
• Blood pressure: systolic >140mmHg or < 90mmHg, diastolic <60 mmHg or >90 mmHg during screening procedures;
• Subject who adhere to a special diet (e.g. low calories, vegetarian etc.);
• Consumption of products containing methylxanthines in the following average quantities: > 3 cups of 200 ml of strong coffee a day;
• Presence of metabolites of illicit drugs (opioids, cannabis) during screening procedures;
• Participation in other clinical trials during the 6 months preceding the study, counting from the day of last product administration.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Reference/Test; 3 mg BDP suppositories (R product) delivered twice daily for 7 days; Washout period (at least 7-day and preferably no more than 9 days); 6 mg BDP suppositories (T product) delivered once daily in the morning for 7 days. Matching placebo suppository will be applied rectally once daily in the evening, on same days as the T product.	Drug: Beclomethasone dipropionate; BDP 3 mg bid (R product) BDP 6 mg qd (T product); Other Names: BDP; Beclomethasone 17,21-dipropionate
Experimental: Test/Reference; 6 mg BDP suppositories (T product) delivered once daily in the morning for 7 days. Matching placebo suppository will be applied rectally once daily in the evening, on same days as the T product.; Washout period (at least 7-day and preferably no more than 9 days); 3 mg BDP suppositories (R product) delivered twice daily for 7 days	Drug: Beclomethasone dipropionate; BDP 3 mg bid (R product) BDP 6 mg qd (T product); Other Names: BDP; Beclomethasone 17,21-dipropionate

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics - Cmax, morning;	Peak exposure after the morning dose (Cmax, morning)	Day 1 and Day 7 of each Period
Pharmacokinetics - Cmax, evening;	Peak exposure after the evening dose (Cmax, evening)	Day 1 and Day 7 of each Period
Pharmacokinetics - AUC0-24	• Total exposure over 24 hours (AUC0-24)	Day 1 and Day 7 of each Period
Pharmacokinetics - AUC0-12	• Total exposure during dosing interval - morning (AUC0-12)	Day 1 and Day 7 of each Period
Pharmacokinetics - AUC12-24	• Total exposure during dosing interval - evening (AUC12-24)	Day 1 and Day 7 of each Period
HPA-axis: 24-hour plasma cortisol - AUC0-24, cortisol	Area under the cortisol level-time curve over 24 hours (AUC0-24, cortisol). AUC will be determined for each subject/treatment at baseline and at Day 7 by the linear trapezoidal rule and ln-transformed. Ln(AUCs) will be used to determine intra-subject difference Day 7 - baseline that will be subject to analysis.	Baseline and Day 7 of each Period
HPA-axis: 24-hour plasma cortisol - AUC0-12, cortisol	Area under the cortisol level-time curve over 12 hours after the morning dose (AUC0-12, cortisol). As above.	Baseline and Day 7 of each Period
HPA-axis: 24-hour plasma cortisol - AUC12-24, cortisol	Area under the cortisol level-time curve over 12 hours after the evening dose (AUC12-24, cortisol). As above.	Baseline and Day 7 of each Period
HPA-axis: 24-hour plasma cortisol - pAUC2-8, cortisol	Partial area under the cortisol level-time curve "covering" 3rd, 4th, 5th, 6th, 7th and 8th hour post morning dose (i.e., between 10:00 and 16:00 hours, that is, between sampling times at 2 and 8 hours post-dose) - a time period during which normal cortisol levels are still relatively high and the strongest suppression after morning dose could be expected (pAUC2-8, cortisol). As above.	Baseline and Day 7 of each Period

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics - trough concentrations	Trough concentrations for R (C12) and T (C24) dosing on Day 1 and Day 7 as well as morning pre-dose (C0)	Day 1 and Day 7 of each Period
Pharmacokinetics - Cmax morning/AUC0-12 ratio	Ratio of the peak exposure after the morning dose to exposure over the subsequent 12 hours (illustrates absorption rate) (Cmax,morning/AUC0-12)	Day 1 and Day 7 of each Period
Pharmacokinetics - Tmax, morning	Time to peak exposure after the morning dose (Tmax,morning)	Day 1 and Day 7 of each Period
Pharmacokinetics - Percent fluctuation (%PTF12)	Day 7 - percent fluctuation over 12 hours after morning dose (%PTF12)	Day 7 of each Period
Pharmacokinetics - Percent fluctuation (%PTF24)	Day 7 - percent fluctuation over 24 hours (%PTF24)	Day 7 of each Period
Pharmacokinetics - Accumulation ratio	Accumulation ratio (Cmax,morning Day 7/Day 1; AUC0-24 Day 7/Day 1). Accumulation ratio will be estimated based on two outcomes: peak exposure after the morning dose (Cmax, morning) and total exposure over 24 hours (AUC0-24).	Day 1 and Day 7 of each Period
HPA axis - Number (proportion) of subjects with cortisol <10 μg/dL	ACTH stimulation test results on the morning of Day 9 (first post-dosing day) dichotomized as "normal" or "abnormal"	Day 8 and 9 of each Period
HPA axis - Number/proportion of subjects with abnormal ACTH stimulation test.	Number (proportion) of subjects with cortisol levels <10 μg/dL at 08:00 a.m. on Day 8 and number (proportion) of subjects with abnormal ACTH stimulation test results in the morning of Day 9 (should any subject be submitted).	Day 8 and 9 of each Period
HPA axis - 24-hour cortisol profile	24-hour cortisol profile: time-point-by-time-point differences Day 7 vs. baseline	Baseline and Day 7 of each Period

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety - Adverse Events	Adverse events reporting	From screening to follow up (approximately 59 days)
Safety - Laboratory values	Incidence of abnormal laboratory test results (Urinalysis, biochemical and haematological tests performed)	At screening, before each period and at follow-up (+21 days after the end of Period 2)

Collaborators and Investigators

• Sponsor: SOFAR S.p.A.

Study record dates

Study Major Dates

• Study Start (Actual): October 22, 2021
• Primary Completion (Actual): April 28, 2022
• Study Completion (Actual): April 28, 2022

Study Registration Dates

• First Submitted: April 26, 2021
• First Submitted That Met QC Criteria: April 29, 2021
• First Posted (Actual): May 5, 2021

Study Record Updates

• Last Update Posted (Actual): May 4, 2022
• Last Update Submitted That Met QC Criteria: May 3, 2022
• Last Verified: May 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Anti-Inflammatory Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Anti-Asthmatic Agents; Respiratory System Agents; Beclomethasone
• Other Study ID Numbers: PSC DS BDP-Once 1

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Yes
• IPD Sharing Supporting Information Type: Study Protocol; Informed Consent Form (ICF); Clinical Study Report (CSR)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No